Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
Fuster D, Planas R, Muga R, Ballesteros AL, Santos J, Tor J, Sirera G, Guardiola H, Salas A, Cabré E, Ojanguren I, Barluenga E, Rey-Joly C, Clotet B, Tural C. Fuster D, et al. Among authors: muga r. AIDS Res Hum Retroviruses. 2004 Dec;20(12):1293-7. doi: 10.1089/aid.2004.20.1293. AIDS Res Hum Retroviruses. 2004. PMID: 15650421
Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus.
Tural C, Tor J, Sanvisens A, Pérez-Alvarez N, Martínez E, Ojanguren I, García-Samaniego J, Rockstroh J, Barluenga E, Muga R, Planas R, Sirera G, Rey-Joly C, Clotet B. Tural C, et al. Among authors: muga r. Clin Gastroenterol Hepatol. 2009 Mar;7(3):339-45. doi: 10.1016/j.cgh.2008.11.019. Epub 2008 Dec 3. Clin Gastroenterol Hepatol. 2009. PMID: 19171202
[Pathogenic interactions between alcohol and hepatitis C].
Fuster D, Tor J, Rey-Joly C, Muga R. Fuster D, et al. Among authors: muga r. Med Clin (Barc). 2012 May 19;138(14):627-32. doi: 10.1016/j.medcli.2011.04.019. Epub 2011 Jun 22. Med Clin (Barc). 2012. PMID: 21696783 Review. Spanish. No abstract available.
Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.
Sanmartin R, de Felipe E, Tor J, Sanvicens A, Barluenga E, Martinez E, Muga R, Jou A, Ojanguren I, López JJ, Clotet B, Tural C. Sanmartin R, et al. Among authors: muga r. AIDS Res Hum Retroviruses. 2012 Oct;28(10):1235-43. doi: 10.1089/AID.2011.0322. Epub 2012 Apr 20. AIDS Res Hum Retroviruses. 2012. PMID: 22443303
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Among authors: muga r. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
263 results